. Author manuscript; available in PMC: 2014 Nov 17.

Published in final edited form as: J Natl Compr Canc Netw. 2011 Feb;9(0 2):S1–25. doi: 10.6004/jnccn.2011.0125

Table 1.

Selected Response and PFS Rates for Front-Line Standard- or High-Dose Imatinib in Clinical Trials

	ELN Study (12-Month Response Rates)¹⁵		TOPS Study (12-Month Response Rates)¹⁶		German CML IV Study (12-Month Response Rates)¹⁷
Response	Imatinib 400 mg/d	Imatinib 800 mg/d	Imatinib 400 mg/d	Imatinib 800 mg/d	Imatinib 400 mg/d	Imatinib 800 mg/d
CCyR^*	58%	64%	66%	70%	50%	63%
MCyR	74%	68%	NR	NR	NR	NR
MMR^‡	41%	49%	40%	46%	31%	56%
PFS^†	84%	91%	95%	97%	88%	88%

Abbreviations: CCyR, complete cytogenetic response; CML, chronic myelogenous leukemia; ELN, European LeukemiaNet; MCyR, major cytogenetic response; MMR, major molecular response; NR, not reported; PFS, progression-free survival; TOPS, Tyrosine Kinase Inhibitor Optimization and Selectivity trial.

Primary end point of ELN study.

^†

Primary end point of the TOPS study

^‡

PFS rate at 36 months (ELN study), at 18 months (TOPS study), and 5 years (German CML IV study).